Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in $6.4mm for Avaxia; adds $5mm

Executive Summary

Avaxia Biologics Inc. (developing therapeutics for gastrointestinal and metabolic diseases) has raised $6.4mm via its Series B financing led by returning backer Cherrystone Angels and new investor Golden Seeds. Other existing shareholders Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, and North Country Angels were joined by first-time backers the Beta Fund, Granite State Angels, the Keiretsu Forum, and Maine Angels, plus individual investors. Avaxia will use the proceeds for a Phase Ib trial of its oral anti-TNF antibody AVX470 for ulcerative colitis. Patient enrollment in the study will begin in early 2013.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies